Amedisys (NASDAQ:AMED) Given New $175.00 Price Target at Truist Financial

Amedisys (NASDAQ:AMEDGet Rating) had its price target trimmed by Truist Financial from $200.00 to $175.00 in a report released on Tuesday morning, The Fly reports. The brokerage currently has a buy rating on the health services provider’s stock.

A number of other analysts have also issued reports on AMED. Royal Bank of Canada reduced their price target on shares of Amedisys from $221.00 to $199.00 and set an outperform rating for the company in a research report on Friday, February 25th. Oppenheimer restated an outperform rating and issued a $200.00 price objective on shares of Amedisys in a report on Friday, April 29th. SVB Leerink dropped their price objective on Amedisys from $131.00 to $117.00 and set a market perform rating on the stock in a report on Friday, May 27th. Stephens dropped their price objective on Amedisys from $155.00 to $125.00 and set an equal weight rating on the stock in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Amedisys from $230.00 to $210.00 in a report on Friday, April 29th. One analyst has rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $173.27.

AMED stock opened at $115.28 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.42. Amedisys has a one year low of $101.61 and a one year high of $276.21. The firm has a market capitalization of $3.76 billion, a PE ratio of 19.84, a P/E/G ratio of 2.10 and a beta of 0.89. The firm has a 50-day moving average of $122.52 and a two-hundred day moving average of $142.33.

Amedisys (NASDAQ:AMEDGet Rating) last posted its quarterly earnings results on Wednesday, April 27th. The health services provider reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.12. The business had revenue of $545.26 million during the quarter, compared to analyst estimates of $557.81 million. Amedisys had a net margin of 8.59% and a return on equity of 19.37%. During the same period in the prior year, the firm earned $1.54 earnings per share. On average, equities research analysts anticipate that Amedisys will post 5.29 earnings per share for the current year.

In other Amedisys news, insider David L. Kemmerly sold 2,500 shares of the stock in a transaction that occurred on Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total transaction of $443,275.00. Following the transaction, the insider now owns 16,336 shares in the company, valued at $2,896,536.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.10% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Covestor Ltd acquired a new stake in shares of Amedisys in the fourth quarter worth $28,000. Allworth Financial LP bought a new position in Amedisys in the first quarter worth $38,000. Harel Insurance Investments & Financial Services Ltd. lifted its position in Amedisys by 55.3% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 233 shares of the health services provider’s stock worth $38,000 after purchasing an additional 83 shares during the period. Confluence Wealth Services Inc. bought a new position in Amedisys in the fourth quarter worth $42,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Amedisys in the first quarter worth $46,000. Institutional investors and hedge funds own 90.47% of the company’s stock.

About Amedisys (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading

The Fly logo

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.